Analyst Price Targets — BIIB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 12:03 pm | — | Wedbush | $201.00 | $202.05 | TheFly | Biogen price target raised to $201 from $196 at Wedbush |
| July 13, 2026 9:11 am | — | Truist Financial | $235.00 | $199.15 | TheFly | Biogen upgraded to Buy from Hold at Truist |
| July 8, 2026 11:37 am | Terence Flynn | Morgan Stanley | $222.00 | $205.70 | TheFly | Biogen price target lowered to $222 from $224 at Morgan Stanley |
| July 7, 2026 11:20 am | — | RBC Capital | $242.00 | $208.46 | TheFly | Biogen price target raised to $242 from $227 at RBC Capital |
| July 6, 2026 2:20 pm | Morten Herholdt | HSBC | $157.00 | $213.26 | TheFly | Biogen price target raised to $157 from $150 at HSBC |
| June 18, 2026 10:43 am | — | Morgan Stanley | $224.00 | $198.67 | TheFly | Biogen price target raised to $224 from $206 at Morgan Stanley |
| June 15, 2026 10:58 am | Salim Syed | Mizuho Securities | $221.00 | $200.05 | TheFly | Biogen price target lowered to $221 from $236 at Mizuho |
| June 8, 2026 10:32 am | — | Needham | $255.00 | $195.34 | TheFly | Biogen upgraded to Buy from Hold at Needham |
| May 27, 2026 9:42 am | Brian Abrahams | RBC Capital | $227.00 | $193.08 | StreetInsider | Biogen (BIIB) PT Raised to $227 at RBC Capital |
| May 15, 2026 10:33 am | — | Piper Sandler | $225.00 | $191.37 | TheFly | Biogen price target raised to $225 from $214 at Piper Sandler |
Latest News for BIIB
Virtual-first, multidisciplinary care model delivers care for adults living with ataxias, connecting them to expert neurologist options nationwide. CHICAGO, July 16, 2026 /PRNewswire/ -- Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative diseases, today announced the launch of a virtual ataxia care program.
BIIB's Alzheimer's drug data presentation reaffirms a phase II setback as investors weigh plans to advance diranersen in phase III despite missed goals.
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Michael J. Parini as Chief Legal Officer, effective August 3, 2026. Parini will serve as a member of Biogen's Executive Committee and report to Christopher A. Viehbacher, President and Chief Executive Officer. In this role, Mr. Parini will have responsibility for oversight of Biogen's global legal and…
Biogen Inc. (BIIB) Presents at Alzheimer's Association International Conference (AAIC Meeting) 2026 Transcript
Biogen NASDAQ: BIIB said data from its Phase 2 CELIA study of diranersen in early Alzheimer's disease provide proof of concept for the tau-targeting therapy, despite the trial not meeting its primary endpoint of demonstrating a predefined dose-response pattern.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.